At JPM some CEOs speak in numbers, others in pos…
Read more →
One of the defining “feelings” at JPM2026 was th…
Read more →
At JPM2026, obesity and metabolic disease (GLP-1…
Read more →
Happy New Year. What you will learn AI and Life …
Read more →
Happy New Year. What you will learn The Current …
Read more →
The second half of 2025’s “top 10” is where the …
Read more →
In 2025, innovation alone was not enough. In 202…
Read more →
In Part 3 of this series, we focus on two “…
Read more →
In Part 2 of this series, we focus on Enher…
Read more →
Around 2025, oncology is entering a new phase in…
Read more →
In the previous installments of this series, we …
Read more →
When investors follow big pharma transactions, i…
Read more →
Alongside oncology and metabolic disease, one of…
Read more →
When we look at the big pharma transactions anno…
Read more →
Among the many big pharma transactions announced…
Read more →
Over the last few months, the pharmaceutical and…
Read more →
Executive Summary｜This collection grounds Parts …
Read more →
Executive Summary｜This playbook turns designs in…
Read more →
Executive Summary｜UK-scale WGS and multi-ancestr…
Read more →
Executive Summary｜The UK’s edge lies in its publ…
Read more →
Executive Summary｜The UK’s 2025 industrial strat…
Read more →
Category: Pharma & Biotech NEWS | Special Fe…
Read more →
Category: Pharma & Biotech NEWS | Special Fe…
Read more →
Category: Pharma & Biotech NEWS | Series “Re…
Read more →